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Associations of IL6R genotypes with IL6R gene expression 
Expression quantitative trait loci (eQTL) analyses were carried out in transcriptomes from 395 healthy blood 
donors (recruited from one centre) and 363 patients with premature myocardial infarction (recruited from 4 
centres) assembled by the Cardiogenics consortium (http://www.cardiogenics.eu). All subjects were of white 
European continental ancestry. RNA was extracted from monocytes and macrophages isolated from whole 
blood with CD14 micro beads (AutoMacs Pro, Miltenyi). Genomic DNA was extracted from peripheral blood by 
standard procedures. Gene expression profiling was performed using Illumina Human Ref-8 arrays (Illumina 
Inc., San Diego, CA). mRNA was amplified and labelled using the Illumina Total Prep RNA Amplification Kit 
(Ambion, Inc., Austin, TX). After hybridization, array images were scanned using the 7 Illumina BeadArray 
Reader and probe intensities were extracted using the Gene expression module of the Illumina’s Bead Studio 
software. Variance Stabilization Transformation (VST) was applied to the raw intensities and quantile 
normalization was performed in the R statistical environment using the Lumi and beadarray packages. Whole-
genome genotyping was carried out using either the Human Custom 1.2M or the Human Quad Custom 670 
arrays from Illumina. The associations of 2 IL6R SNPs (rs4537545 and rs4129267) with transcript levels of 
IL6R were assessed using additive regression models adjusted for age, gender and centre. 
 
Data on associations of IL6R genotypes with IL6R mRNA levels in 1,490 healthy individuals from the 
Gutenberg Heart Study were accessed online. Details of the methods used in this study have been described 
previously.24 Briefly, the participants were healthy population subjects aged between 35 and 74 living in Mainz, 
Germany. Following separation of monocytes and purification of cells, genome-wide expression analysis was 
conducted using the Illumina HT-12 v3 BeadChip and the Affymetrix Human SNP array 6.0. The associations 
of 2 IL6R SNPs (rs4537545 and rs4129267) with IL6R transcript levels were assessed using additive 
regression models adjusted for age and gender. 
 
To test whether the change in IL-6 levels in response to an inflammatory stimulus is affected by carriage of 
358Ala, monocytes from 205 healthy blood donors were stimulated with LPS 0ng/ml, LPS 1ng/ml and LPS 
5ng/ml. IL-6 concentration was assessed at baseline and 4 hours post-stimulation. The relationship between 
IL-6 production and IL6R rs4537545 genotype was calculated relative to LPS 0ng/ml using linear regression. 
 
Data on associations with IL6R genotypes with IL6R mRNA levels were also looked up in in liver cells from 427 
European individuals,27 lymphoblastoid cell lines from multiple European adult populations,28 T-cell or 
lymphoblastoid cell lines from umbilical cords of 75 individuals,26 or lymphoblastoid cell lines from 166 healthy 
female twins.25  























































ADVANCE     0.43  282 288 288 282 311 310 308 312 312    301   278 312 
AGES     0.43  3214 3216 3216 3216 3215 3213 3211 3216 3212    3215   775 2574 
BHF-FHS     0.42                 2101 2426 
BLOODOMICS-1     0.39                 1462 1222 
BLOODOMICS-2     0.39                 1910 1932 
CIHD     0.42                 5111 6626 
COPEN     0.42  8851 9114 9100  9122 9098 9075 9080 9083    8281 8867  1968 7162 
COROGENE     0.32         1856 1870         
CUDAS/CUPID     0.40  1001 1001 1001 995 1001 1001 1001 1001 1001   933 968 984  548 1001 
DECODE     0.43  1685 11998 11952 6719 10852 27877 6123 21382     6215   7370 27059 
DILGOM     0.28  3975 3975 3975 3986 3980 3996 3975 3976 3996   3941 3975   128 3868 
EPIC-NL     0.39  2427 2427 2427  2427 2427 2427 1638 2009    2427   1221 1833 
FHS-G3     0.41   3531 3532 3532 3532 3528 3517 3531 3526   3494 3515     
FHS-offspring     0.40  2648 2678 2683 2622 2792 2685 2662 2793 2692   2667 2672 2671    
Framingham     0.41                 489 7338 
FUSION_1     0.31  1560 1587 1587 1594 1619 1620 1613 578 1651       309 2022 
FUSION_2     0.39                 165 2633 
GerMIFS_1     0.39       1531          970 1604 
GerMIFS_2     0.39  489 499 499  499 485          1222 1284 
GLACIER     0.35  3144 3168 3492 5970 5930 5991 108 5951 5951         
Guangzhou‡     0.34  1904 1905 1905 1905 1899 1905 1905     1235 1871     
HealthABC‡     0.15       1168     577 1116 1172     
HPS     0.39                 2703 2884 
HUNT     0.37  1222 1318 1319  1308 1284 1290 1325 1325       159 1299 
HVHS     0.42  744 1046 813  1070 1069  1070 1070       221 849 
INCHIANTI     0.40  1064 1064 1064 1064 1054 1012 1011 1093 967  1068 1067 1058 1058  106 1163 
InterHeart-1†‡§                      1137 1215 
InterHeart-2†§                      796 895 
ISIS†§                      2073 1493 
LOLIPOP‡     0.31  5430 5589 5589 5589 5590 5586 5589 5590 5589    4797   2979 3556 
LURIC     0.40  647 647 647 647 647 647 641     645 647 646  2493 693 
METSIM     0.27  1727 1728 1728 1729 1729 1728 1728 1729 1729    1679   117 1823 
MOGERAUG     0.40  1210 1662 478 478 1662 1655 1208 1662 1662   1662 1660 1206  272 1390 
MrOS     0.40      2004 2030  2030 2029    1980   587 2195 
NHS     0.40       3192 2213 2035 3219   972 988   301 976 
ORCADES     0.36  766 766 766 766 760 760 760 766 766    761 761  107 766 
PennCATH     0.42                 1027 489 
PIVUS     0.38  881 883 883 883 882 886 877 885 886   871 880   94 885 
PROCARDIS     0.42  2957 2957 2957  2904 2908  2955 2969    2954 2954  2121 2969 
PROMIS‡     0.30                 4741 4575 
ROTT     0.40   378   377 377 329     379 362 257  1317 3730 
SARDINIA     0.26  5424 5424 5424 5424 5418 5425 5425 5705 5432   5325 5138 5420  44 5705 
SCARF     0.37  383 383 385 381 380 385 383 383    374 378 380  336 386 
SHEEP     0.40  2563 2590 2613 2356 2601 2595 2601 2558 2614   1615 1935 2442  1135 1481 
ULSAM     0.39  967 970 972 971 971 968 954 972 971   889 941 445  233 942 
WGHS     0.41  23178 23178 23178  23041 22880 20558 23268 23286    23178 22262  315 22971 
Total         0.39  80343 95970 94473 51109 99577 122222 81492 109340 89817  1645 27185 83948 50353  51441 136226 
  
5 
MAF, minor allele frequency; LDL-C, low-density lipoprotein cholesterol; HDL-C high-density lipoprotein cholesterol; TG, triglyceride; FBG, fasting blood glucose; SBP, systolic blood pressure; BMI, body mass index; 
WC waist circumference; s-IL-6R, soluble interleukin-6 receptor; IL-6, interleukin-6; CRP, C-reactive protein; Fib, fibrinogen. 
* Study acronyms are listed in the Supplementary Appendix; † For these studies, data were extracted from publications; ‡ These studies were based in populations not of predominantly white European descent; § Calculated in people 
without cardiovascular disease.  






Supplementary Table 2: Study level characteristics of studies contributing to analyses of the IL6R genotypes 
 
 
CAD, angiographically defined coronary stenosis; GP, general practitioner; MI, myocardial infarction. 
* Study acronyms are listed in the Supplementary Appendix; † Diagnosis of myocardial infarction was based on: ● patient self report, ●● hospital discharge records, ●●● at least 2 of: clinical features, cardiac markers, and ECG; 





 Coronary disease 
 






ADVANCE Case-control USA Healthcare register  Illumina 550K array  MI & CAD ●● >50% stenosis or Revascularisation§ 
AGES Cohort Iceland Population register  Illumina 370CNV BeadChip array   MI & CAD ●●● Revascularisation§ 
BHF-FHS Case-control England Population register  Affymetrix 500K array  CAD  >50% stenosis or Revascularisation§ 
BLOODOMICS-1 Case-control Netherlands Hospital admissions/blood donors  Illumina IBC 50K array  MI ●●●  
BLOODOMICS-2 Case-control Germany Hospital admissions/general population  Illumina IBC 50K array  CAD  >50% stenosis or Revascularisation§ 
CIHDS Case-control Denmark Hospital admissions/general population  TaqMan  MI & CAD ●● Stenosis‡ 
COPEN Cohort Denmark Population register  TaqMan  MI & CAD ●●  
COROGENE  Finland Hospital admissions       
CUDAS/CUPID Case-control Australia Electoral rolls/Hospital admissions  TaqMan  MI & CAD ● >50% stenosis 
DECODE Cohort Iceland Population register  Illumina 370CNV BeadChip array   MI & CAD ●●● Revascularisation§ 
DILGOM Cohort Finland Population register  Illumina 610-Quad array  MI & CAD ●●● Revascularisation§ 
EPIC-NL Nested case-control Netherlands Population register  Illumina IBC 50K array  MI ●  
FHS-G3 Cohort USA Household listings  Affymetrix 500K array     
FHS-offspring Cohort USA Household listings  Multiplex     
Framingham Cohort USA Population register  Multiplex  MI ●●●  
FUSION_1 Cohort Finland Hospital admissions/general population  Illumina HumanHap300 BeadChip  MI ●  
FUSION_2 Cohort Finland Hospital admissions/general population  Illumina Cardio-Metabochip     
GerMIFS_1 Case-control Germany Cardiac rehabilitation/general population  Affymetrix 500K array  MI ●●●  
GerMIFS_2 Case-control Germany Cardiac rehabilitation/general population  Affymetrix 500K array  MI ●●●  
GLACIER Cohort Sweden Population register  OpenArray SNP Genotyping System     
Guangzhou Cohort China Population register  TaqMan     
HealthABC Cohort USA Population register  Sequenom Mass array     
HPS Clinical trial UK Hospital admissions/general population  Illumina 610-Quad array  MI & CAD ●  
HUNT Cohort Norway Population register  Illumina Cardio-Metabochip  MI ●  
HVHS Case-control USA GP lists  Illumina GoldenGate  MI ●●●  
INCHIANTI Cohort Italy Population register  TaqMan  MI ●  
InterHeart-1 Case-control India Hospital admissions/general population  Illumina GoldenGate  MI ●●●  
InterHeart-2 Case-control Europe Hospital admissions/general population  Illumina GoldenGate  MI ●●●  
ISIS Case-control UK Hospital admissions/general population  TaqMan  MI ●●  
LOLIPOP Case-control UK General population  Illumina IBC 50K array  MI & CAD ●●●  
LURIC Cross-sectional Germany Elective angiography patients  Illumina IBC 50K array  MI & CAD ●●● >50% stenosis 
METSIM Cohort Finland Population register  Illumina Cardio-Metabochip  MI ●  
MOGERAUG Case-cohort Germany Population register  Illumina IBC 50K array  MI ●●●  
MrOS Cohort Sweden Population register  KASPar/TaqMan  MI ●●  
NHS Nested case-control USA Occupational  TaqMan  MI ●●●  
ORCADES Cohort Scotland Population register  Illumina HumanHap300 BeadChip  MI   
PennCATH Case-control USA Hospital admissions  Illumina IBC 50K array  CAD  >50% stenosis 
PIVUS Cohort Sweden Population register  Illumina GoldenGate  MI ●●●  
PROCARDIS Case-control Europe Hospital admissions/general population  Illumina IBC 50K array  MI & CAD ●●● Stenosis‡ 
PROMIS Case-control Pakistan Hospital admissions  Illumina IBC 50K / 660-Quad arrays  MI ●●●  
ROTT Cohort Netherlands Population register  Illumina 550K array  MI & CAD ●●●  
SARDINIA Cohort Italy Population register  Affymetrix 500K array  MI   
SCARF Case-control Sweden Hospital admissions/general population    MI ●●  
SHEEP Case-control Sweden GP lists, electoral roles  TaqMan  MI ●●●  
ULSAM Cohort Sweden Population register  Illumina GoldenGate  MI ●●  
WGHS Cohort USA Occupational  Illumina Infinium II   MI ●●●  
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BeckCoult, Beckman Coulter; BioSourceInt, BioSource International; BoehrMann, Boehringer Mannheim; CIA, chemiluminescence immunoassay; DiacloneRes, Diaclone Research; DiagStago, Diagnostica Stago; ELISA, 
enzyme-linked immunosorbent assay; FPT, fibrin polymerization time; ImmuliteDiag, Immulite Diagnostic; INA, immunonephelometric assay; InstrLab, Instrumentation Laboratory; IRMA, immunoradiometric assay; ITA, 
immunoturbidimetry assay; OrionDiag, Orion Diagnostica; PT, prothrombin time; RandoxLab, Randox Laboratories; RochDiag, Roche Diagnostics; TCA, thrombin clotting assay; UniVermont, University of Vermont. 
























Manufacturer  n Sample 
source 





ADVANCE            301 Serum ITA / ELISA Denka Seiken      
AGES            3215 Serum ITA RochDiag      
COPEN            8281 Plasma ITA / INA Dade Behring  8867 Plasma ITA BoehrMann 
CUDAS/CUPID       933 Serum ELISA R&D Systems  968 Serum ITA RochDiag  984 Plasma Clauss   
DECODE            6215         
DILGOM       3941 Serum CIA ImmuliteDiag  3975         
EPIC-NL            2427 Plasma ITA BeckCoult      
FHS-G3       3494     3515         
FHS-offspring       2667 Serum ELISA R&D Systems  2672 Plasma ELISA Dade Behring  2671 Plasma Clauss DiagStago 
Guangzhou       1235     1871  ITA BioSystems SA      
HealthABC  577 Serum ELISA R&D Systems  1116 Serum ELISA R&D Systems  1172 Serum ELISA Calbiochem      
INCHIANTI  1068 Serum ELISA BioSource  1067 Serum ELISA BioSourceInt  1058 Serum INA Dade Behring  1058 Plasma Clauss DiagStago 
LOLIPOP            4797 Serum ITA RochDiag      
LURIC       645 Plasma ELISA R&D Systems  647 Plasma INA Dade Behring  646  Clauss Dade Behring 
METSIM            1679 Plasma ITA RochDiag      
MOGERAUG       1662 Serum ELISA R&D Systems  1660 Plasma IRMA / INA Dade Behring  1206 Plasma INA Dade Behring 
MrOS            1980  Quick 
read 
OrionDiag      
NHS       972 Plasma ELISA R&D Systems  988 Plasma ITA Denka Seiken      
ORCADES            761 Plasma ELISA   761    
PIVUS       871 Serum Biochip RandoxLab  880         
PROCARDIS            2954 Plasma INA Dade Behring  2954 Plasma Clauss InstrLab 
ROTT       379 Plasma ELISA R&D Systems  362 Serum INA Immage  257 Plasma PT-based InstrLab 
SARDINIA       5325 Serum ELISA R&D Systems  5138 Serum ELISA UniVermont  5420    
SCARF       374  ELISA R&D Systems  378     380 Plasma TCA InstrLab 
SHEEP       1615 Serum ELISA DiacloneRes  1935 Plasma INA Dade Behring  2442 Plasma FPT In-house 
ULSAM       889 Serum ELISA R&D Systems  941 Serum INA Dade Behring  445  INA BeckCoult 
WGHS            23178 Blood ITA Denka Seiken  22262 Plasma ITA RochDiag 
Total  1645     27185     83948     50353    
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ATTICA 1442 50.50 (11.00) 744 (51.6%)  1442 Serum ELISA R&D Systems  1442 Serum INA Behring  1180 Plasma ITA Dade Behring 
BRHS 1199 51.92 (5.38) 1199 (100.0%)  1199 Serum ELISA R&D Systems  1199 Serum MEIA Abbott      
BRUN 817 57.86 (11.39) 398 (48.7%)       817 Plasma ITA/INA Behring  817 Plasma Clauss  
CAPS 832 57.25 (4.58) 832 (100.0%)       832 Plasma EIA Behring  832 Plasma INA/Clauss  
CHS1 3865 72.33 (5.22) 1479 (38.3%)  3572 Plasma ELISA R&D Systems  3865 Plasma ELISA In-house  3841 Plasma Clauss  
CHS2 462 72.31 (5.22) 176 (38.1%)  437 Plasma ELISA R&D Systems  462 Plasma ELISA In-house  462 Plasma Clauss  
COPEN 7161 59.58 (13.46) 3070 (42.9%)       7161 Serum ITA DAKO  7161 Plasma ITA BoehrMann 
FIA 1495 54.99 (7.61) 1074 (71.8%)  1495     1495 Plasma CIA Immulite      
FINRISK92 446 55.49 (5.94) 235 (52.7%)       446 Serum CIA Immulite  446 Plasma INA InstrLab 
FINRISK97 1156 60.92 (8.52) 1156 (100.0%)       1156 Serum ELISA Eucardio Lab  1156 Plasma Clauss InstrLab 
FLETCHER 620 56.85 (14.43) 478 (77.1%)  572 Plasma ELISA R&D Systems  620 Plasma INA Behring  618 Plasma INA Behring 
HPFS 730 63.11 (8.31) 730 (100.0%)  729 Plasma ELISA R&D Systems  730 Plasma ITA Denka Seiken  730 Plasma ITA Kamiya Biomedical 
KIHD 1879 52.37 (5.36) 1879 (100.0%)       1879 Serum CIA Immulite  1879 Plasma Clauss  
LEADER 434 67.09 (9.11) 434 (100.0%)       434 Serum CIA Immulite  434  Clauss  
MESA 6715 62.15 (10.24) 3170 (47.2%)  6568 Serum ELISA R&D Systems  6715 Plasma INA Behring  6700 Serum INA Dade Behring 
MOGERAUG2 1221 58.67 (8.42) 1221 (100.0%)       1221 Serum IRMA In-house  1221 Plasma INA Behringwerke 
MOGERAUG3 3150 54.89 (10.43) 1595 (50.6%)       3150 Serum IRMA In-house  3150 Plasma INA Dade Behring  
MOSWEGOT 675 49.04 (9.51) 334 (49.5%)       675     675 Plasma Clauss  
NHANES3 2894 60.70 (13.05) 1153 (39.8%)       2894 Serum INA Behring  2894 Plasma Clauss Organon Teknika 
NHS 712 60.33 (6.52) 0 (0.0%)  679 Plasma ELISA R&D Systems  712 Plasma ITA Denka Seiken  712 Plasma ITA Kamiya Biomedical 
NSHS 1421 53.93 (14.91) 681 (47.9%)  1421 Plasma ELISA R&D Systems  1421 Plasma INA Behring      
PRIME 891 55.22 (2.79) 891 (100.0%)       891 Plasma INA Behring  891 Plasma Clauss DiagStago 
QUEBEC 1913 56.29 (6.94) 1913 (100.0%)       1913 Plasma INA Behring  1913  Clauss  
ROTT 1816 69.13 (7.99) 614 (33.8%)       1816 Serum INA Immage  1816 Plasma PT-based InstrLab 
SHS 3166 59.73 (7.86) 1148 (36.3%)       3166 Plasma ELISA In-house  3166 Plasma Clauss (m) DiagStago 
SPEED 1565 57.68 (4.37) 1565 (100.0%)       1565 Plasma EIA Behring  1565 Plasma INA / Clauss  
TARFS 481 51.60 (12.28) 241 (50.1%)       481 Serum INA Behring  481 Plasma Clauss (m) Dade Behring 
ULSAM 992 71.42 (1.74) 992 (100.0%)  939 Serum ELISA R&D Systems  992 Serum INA Behring  435  INA BeckCoult 
WHI-HaBPS 1369 68.42 (6.35) 0 (0.0%)       1369 Plasma ITA Denka Seiken  1369 Plasma Clauss DiagStago 
WHS 27754 54.68 (7.08) 0 (0.0%)       27754 Plasma ITA Denka Seiken  27754 Plasma ITA Kamiya Biomedical 
Total 79273 59.22 (8.84) 29402 (37.1%)  19053     79273     74298    
 
BeckCoult, Beckman Coulter; BoehrMann, Boehringer Mannheim; CIA, chemiluminescence immunoassay; DiagStago, Diagnostica Stago; ELISA, enzyme-linked immunosorbent assay; INA, immunonephelometric 
assay; InstrLab, Instrumentation Laboratory; IRMA, immunoradiometric assay; ITA, immunoturbidimetry assay; m, modified Clauss method. 
IL-6, interleukin-6; CRP, C-reactive protein. 
* Study acronyms are listed in the Supplementary Appendix. 




Supplementary Table 5: Association of IL6R genotype with levels of inflammation markers and risk of 
coronary heart disease, in analyses restricted to studies based in populations of predominantly white 




Total no. of participants 
with available data 
Percentage mean difference, or 
odds ratio, (95% CI) per minor allele 
P-value for 
association 
    
Interleukin-6 24,834 13.5% (9.3 to 17.6%) 1.5x10-10 
C-reactive protein 76,108 -7.4% (-9.2 to -5.8%) 6.9x10-18 
Fibrinogen 50,353 -1.0% (-1.3 to -0.7%) 4.8x10-12 
    
Coronary heart disease 
cases vs. controls 
42,925 vs. 127,200 0.963 (0.942 to 0.981) 9.9x10-5 
 























Data above from participants in the Cardiogenics Consortium (see Appendix for members). 
 
Similarly, no statistically significant associations were seen between either SNP and IL6R expression in monocytes from 1,409 healthy individuals from the Gutenberg 
Heart Study (Genome-wide P>1x10-6; threshold for statistical significance=5.87x10-12),24 in liver cells from 427 European individuals,27 lymphoblastoid cell lines from 
multiple European populations,28 T-cell or lymphoblastoid cell lines from umbilical cords of 75 individuals,26 or lymphoblastoid cell lines from 166 healthy female twins.25 
 
  rs4129267  rs4537545 
Gene  Beta P-value  Beta P-value 
       
Monocytes 
      
MI cases (n=363)  -0.0272 0.26  -0.0247 0.30 
Healthy blood donors (n=395)  0.0337 0.19  0.0324 0.20 
       
Macrophages 
      
MI cases (n=363)  -0.0103 0.45  -0.0088 0.51 
Healthy blood donors (n=395)  0.0309 0.13  0.0276 0.17 
11 
Supplementary Table 7: Randomized trials contributing to analyses of tocilizumab (TCZ) 
 




























RA 24 TCZ 8 mg/kg 286  206  171  254  -  240  224  248  252 AMBITION S1 
  
Tabular 
  Placebo + MTX† 284  209  138  248  -  239  233  243  246 
Ito et al S4 CrD 12 TCZ 8 mg/kg‡ 10  10  10  10  10  -  -  -  - 




  Placebo‡ 13  13  13  13  13  -  -  -  - 
LITHE S5 RA 52 TCZ 8 mg/kg + MTX 398  -  -  285  -  271  265  280  282 
   TCZ 4 mg/kg + MTX 399  -  -  247  -  239  236  251  252 
 
Tabular 
  Placebo + MTX 393  -  -  157  -  156  156  157  158 
Nishimoto et al S9 RA 12 TCZ 8 mg/kg 55  -  -  -  55  -  -  -  - 




  Placebo 53  -  -  -  53  -  -  -  - 
OPTION S11 RA 24 TCZ 8 mg/kg + MTX 205  158  116  167  -  158  155  169  169 
    TCZ 4 mg/kg + MTX 213  143  94  151  -  151  151  160  160 
  
Tabular 
  Placebo + MTX 204  119  82  121  -  111  110  122  122 
RADIATE S13 RA 24 TCZ 8 mg/kg + MTX 170  87  65  117  -  113  108  115  117 
    TCZ 4 mg/kg + MTX 161  88  65  101  -  100  97  103  105 
  
Tabular 
  Placebo + MTX 158  47  37  61  -  65  64  67  67 




  DMARDs 10  -  10  10  -  -  -  -  - 




  MTX 37  -  -  37  -  -  -  -  - 
TOWARD S21 RA 24 TCZ 8 mg/kg + DMARDs 803  516  413  686  -  645  617  672  682 
  
Tabular 
  Placebo + DMARDs 413  269  194  301  -  285  280  298  302 
Total     4394  1865  1417  3028  185  2773  2696  2885  2914 
 
CrD, Crohn’s disease; CRP, C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; IL, interleukin; JIA, juvenile idiopathic arthritis; MTX, methotrexate; RA, rheumatoid arthritis. 
 † Received rescue therapy (TCZ 8mg/kg) on worsening of symptoms at the investigator’s discretion; ‡ Intervention was administered biweekly; § Intervention was alternating injections of tocilizumab and placebo; - did 
not provide sufficient information to be included in analysis. 
References for each of the studies listed in this table are provided in the Supplementary Appendix. 
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r2 values are based on the CEU HapMap2 population. rs4537545 represents a C>T exchange; rs8192284 represents Asp358Ala; rs4129267 represents a C>T exchange. rs8192284 has recently been merged into rs2228145. In 
all genetic analyses, “1/1” is used to denote common homozygotes, “1/2” for heterozygotes and “2/2” for rare homozygotes.  





exon 7 exon 8 exon 9
r2 = 0.964; Distance = 706bp
r2 = 0.964; Distance = 8091bp
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Percentage mean difference was calculated in reference to the overall mean for each markers among common homozygotes 
 
Assessments of overall heterogeneity: A. χ214 = 17.5 (P = 0.233); I2 = 20% (0% to 56%). B. χ224 = 38.8 (P = 0.03); I2 = 38% (0% to 62%). C. χ213 = 15.3 (P = 0.29); I2 = 15% (0% to 53%) 
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Assessment of overall heterogeneity: X238 = 44.84 (P=0.21); I2 = 15% (0% to 43%). 
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Vertical lines represent 95% confidence intervals. Details of trials contributing to these analyses are provided in Supplementary Table 7. 
By comparison, the absolute mean differences (95% CI) seen by IL6R genotype displayed in Figure 1 are: 
sIL6-R (ng/ml):  1/2: +10.4 (+8.9, +11.9)  2/2: +22.5 (+18.7, 26.3) 
IL6 (ng/L):  1/2: +0.16 (+0.09, +0.24)  2/2: +0.56 (+0.40, +0.71) 
CRP (mg/L):  1/2: -0.1 (-0.2, -0.05)  2/2: -0.4 (-0.5,-0.3) 
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NISHIMOTO none RA published
NISHIMOTO none RA published
NISHIMOTO none RA published
n
 
Box sizes are proportional to the number of participants in each trial. 
After exclusion of 2 outlying trials - (1) the AMBITION trial, the only trial to use methotrexate in a “methotrexate-naïve” population in its placebo arm, (2) the Ito trial, the only trial 
set in Crohn’s disease patients, pooled mean differences (95% CI) and heterogeneity statistics were: 
IL-6R: 0mg/kg 3 (-6,11), I2=77%,p=0.01. 4mg/kg 110 (91,128), I2=0%,p=0.83. 8mg/kg 453 (394,513), I2=94%,p<0.001. 
IL-6: 0mg/kg 0.9 (-6.8,8.5), I2=38%,p=0.18. 4mg/kg -24.0 (-38.4,-9.6), I2=51%,p=0.15. 8mg/kg 19.5 (5.8,33.2), I2=70%,p=0.02. 
CRP: 0mg/kg -0.35 (-0.53,-0.17), I2=0%,p=0.95. 4mg/kg -1.26 (-1.62,-0.90), I2=44%,p=0.17. 8mg/kg -2.45 (-2.61,-2.28), I2=15%,p=0.32. 
Fibrinogen: 0mg/kg 18 (-3,39). 4mg/kg -84 (-105,-63). 8mg/kg -232 (-249,-214). 
19 







































































































































Box sizes are proportional to the number of participants in each trial. 
After exclusion of 1 outlying trial - the AMBITION trial, the only trial to use methotrexate in a “methotrexate-naïve” population in its placebo arm, pooled mean differences 
(95% CI) and heterogeneity statistics were: 
Total cholesterol: 0mg/kg 0.13 (0.05,0.20), I2=45%,p=0.14. 4mg/kg 0.44 (0.37,0.51), I2=0%,p=0.81. 8mg/kg 0.81 (0.73,0.89), I2=53%,p=0.10. 
LDL-C: 0mg/kg 0.08 (0.01,0.14), I2=46%,p=0.14. 4mg/kg 0.34 (0.28,0.40), I2=0%,p=0.85. 8mg/kg 0.54 (0.48,0.61), I2=38%,p=0.18. 
HDL-C: 0mg/kg 0.03 (0.01,0.05), I2=0%,p=0.51. 4mg/kg 0.08 (0.05,0.10), I2=0%,p=0.749. 8mg/kg 0.12 (0.10,0.15), I2=35%,p=0.20. 
Triglycerides: 0mg/kg 0.03 (-0.02,0.07), I2=0%,p=0.94. 4mg/kg 0.08 (0.01,0.15), I2=38%,p=0.20. 8mg/kg 0.34 (0.29,0.39), I2=0%,p=0.78. 
 
Supplementary Appendix.  
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List of acronyms for the genetic studies 
 
Study Acronym Study Name 
ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation 
AGES AGES Reykjavik Study: The Reykjavik Study of Healthy Aging for the New Millennium 
BHF-FHS British Heart Foundation Family Heart Study 
BLOODOMICS-1 Bloodomics Consortium, Dutch Part 
BLOODOMICS-2 Bloodomics Consortium, German Part 
CIHDS Copenhagen Ischemic Heart Disease Study 
COPEN Copenhagen City Heart Study 
COROGENE Genetic Predisposition of Coronary Heart Disease in Patients Verified with Coronary Angiogram? 
CUDAS / CUPID Carotid Ultrasound Disease Assessment Study / Carotid Ultrasound in Patients with Ischaemic Heart Disease Study 
DECODE Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe 
DILGOM Dietary, Lifestyle and Genetic Determinants of Obesity and Metabolic Syndrome Study 
EPIC-NL European Prospective Investigation into Cancer and Nutrition, Netherlands Centre 
FHS-G3 Framingham Generation Three Cohort 
FHS-offspring Framingham Offspring Cohort 
Framingham Framingham Heart Study 
FUSION_1 Finland-United States Investigation of NIDDM Genetics Study 1 
FUSION_2 Finland-United States Investigation of NIDDM Genetics Study 2 
GerMIFS_1 German MI Family Study 1 
GerMIFS_2 German MI Family Study 2 
GLACIER Gene x Lifestyle Interactions And Complex Traits Involved in Elevated Disease Risk Study 
Guangzhou Guangzhou Biobank Cohort Study 
HealthABC Health, Aging, and Body Composition Study 
HPS Heart Protection Study 
HUNT Nord-Trøndelag Health Study 
HVHS Heart and Vascular Health Study 
INCHIANTI Invecchiare in Chianti Study 
InterHeart-1 InterHeart Study, Indian Asian Part 
InterHeart-2 InterHeart Study, European Part 
ISIS International Study of Infarct Survival 
LOLIPOP London Life Sciences Prospective Population Study 
LURIC Ludwigshafen Risk and Cardiovascular Health Study 
METSIM Metabolic Syndrome In Men Study 
MOGERAUG MONICA/KORA Augsburg 
MrOS Osteoporotic Fractures in Men Study 
NHS Nurses’ Health Study 
ORCADES Orkney Complex Disease Study 
PennCATH University of Pennsylvania Catheterization Study 
PIVUS Prospective Investigation of the Vasculature in Uppsala Seniors Study 
PROCARDIS Precocious Coronary Artery Disease Study 
PROMIS Pakistan Risk of Myocardial Infarction Study 
ROTT The Rotterdam Study 
SARDINIA Sardinia Study of Aging 
SCARF Stockholm Coronary Artery Risk Factor Study 
SHEEP Stockholm Heart Epidemiology Program 
ULSAM Uppsala Longitudinal Study of Adult Men 
WGHS Women's Genome Health Study 
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List of acronyms for the observational studies (ERFC) 
 
Study Acronym Study Name 
ATTICA ATTICA Study 
BRHS British Regional Heart Study 
BRUN Bruneck Study 
CAPS Caerphilly Study  
CHS1 Original cohort of the Cardiovascular Health Study 
CHS2 Supplemental African-American cohort of the Cardiovascular Health Study 
COPEN Copenhagen City Heart Study 
FIA First Myocardial Infarction in Northern Sweden 
FINRISK92 Finrisk Cohort 1992 
FINRISK97 Finrisk Cohort 1997 
FLETCHER Fletcher Challenge Blood Study 
HPFS Health Professionals Follow-Up Study 
KIHD Kuopio Ischaemic Heart Disease Study 
LEADER Lower Extremity Arterial Disease Event Reduction Trial 
MESA Multi-Ethnic Study of Atherosclerosis 
MOGERAUG2 MONICA/KORA Augsburg Surveys S2 
MOGERAUG3 MONICA/KORA Augsburg Surveys S3 
MOSWEGOT MONICA Göteborg Study 
NHANES3 Third National Health and Nutrition Examination Survey 
NHS Nurses’ Health Study 
NSHS Nova Scotia Health Survey 
PRIME Prospective Epidemiological Study of Myocardial Infarction 
QUEBEC Québec Cardiovascular Study 
ROTT The Rotterdam Study 
SHS Strong Heart Study 
SPEED Speedwell Study 
TARFS Turkish Adult Risk Factor Study 
ULSAM Uppsala Longitudinal Study of Adult Men 
WHI-HaBPS Women's Health Initiative (Hormones and Biomarkers Predicting Stroke in Women) 




Search strategy used to identify published reports on tocilizumab 
 
Published studies were identified through electronic searches using Medline and by scanning reference lists of 
articles identified for all relevant studies (including review articles). The computer-based searches combined 
search terms related to tocilizumab without language restriction. 
 
Pubmed strategy: 
atlizumab OR tocilizumab OR Actemra OR RoActemra OR (MRA AND ("Interleukin 6" OR "Plasmacytoma 
Growth Factor" OR "Growth Factor, Plasmacytoma" OR "B-Cell Differentiation Factor-2" OR "B Cell 
Differentiation Factor 2" OR "B-Cell Stimulatory Factor 2" OR "B-Cell Stimulatory Factor-2" OR "BSF-2" OR 
"Differentiation Factor, B-Cell" OR "Differentiation Factor, B Cell" OR "Differentiation Factor-2, B-Cell" OR 
"Differentiation Factor 2, B Cell" OR "Hepatocyte-Stimulating Factor" OR "Hepatocyte Stimulating Factor" OR 
"Hybridoma Growth Factor" OR "Growth Factor, Hybridoma" OR "IFN-beta 2" OR "IL-6" OR "IL6" OR "MGI-2" 
OR "Myeloid Differentiation-Inducing Protein" OR "Differentiation-Inducing Protein, Myeloid" OR "Myeloid 
Differentiation Inducing Protein" OR "B Cell Stimulatory Factor-2" OR "B Cell Stimulatory Factor 2" OR "B-Cell 
Differentiation Factor" OR "B Cell Differentiation Factor")) 
 
References:  
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Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in 
patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.  
S2. Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen 
J, Thomson D, Kishimoto T; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the 
interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an 
incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–29. 
S3. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, 
Price R, Yoshizaki K, Nishimoto N, Kishimoto T, Panayi GS. Therapeutic benefit of blocking interleukin-6 
activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-
blind, placebo-controlled, dose-escalation trial. Arthritis Rheum. 2002;46(12):3143–50.  
S4. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, 
Nishimoto N, Yoshizaki K, Shimoyama T, Kishimoto T. A pilot randomized trial of a human anti-interleukin-6 
receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 2004;126(4):989–96. 
S5. Kremer JL, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. 
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to 
methotrexate at 1 year: The LITHE study. Arthritis Rheum. 2010 Nov. [Epub ahead of print] 
S6. Nakashima Y, Kondo M, Harada H, Horiuchi T, Ishinishi T, Jojima H, Kuroda K, Miyahara H, Nagamine R, 
Nakashima H, Otsuka T, Saikawa I, Shono E, Suematsu E, Tsuru T, Wada K, Iwamoto Y. Clinical evaluation of 
tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in 
combination with methotrexate. Mod Rheumatol. 2010;20(4):343–52.  
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Search strategy used to identify reports of IL6R variant associations 
 
Published studies were identified through electronic searches using Medline and by scanning reference lists of 
articles identified for all relevant studies (including review articles). The computer-based searches combined 
search terms related to the interleukin-6 receptor and relevant genetic variants without language restriction. 
 
Pubmed strategy: 
genetic[tw] OR genetic research[mh] OR genetics[tw] OR medical genetics[mh:noexp] OR genetics, 
population[mh] OR genomics[mh:noexp] OR genomic[tw] OR genomics[tw] OR molecular epidemiology[tw] OR 
molecular epidemiology[mh] OR molecular association[tw] OR genes[mh] OR genes[tw] OR gene[tw] OR 
allele[tw] OR alleles[tw] OR allelic[tw] OR polymorphism[tw] OR polymorphisms[tw] OR polymorphic[tw] OR 
SNP[tw] OR mutation[tw] OR mutations[tw] OR mutant[tw] OR mutants[tw] OR homozygote[tw] OR 
homozygotes[tw] OR homozygotic[tw] OR heterozygote[tw] OR heterozygotes[tw] OR heterozygotic[tw] OR 
genotype[mh] OR genotype[tw] OR genotypes[tw] OR genotypic[tw] OR genotyped[tw] OR phenotype[mh] OR 
phenotype[tw] OR phenotypes[tw] OR phenotypic[tw] OR phenotyped[tw] OR haplotype[tw] OR haplotypes[tw] 
OR haplotypic[tw] OR haplotyped[tw] OR genetic variant*[tw] OR genetic variation[tw] OR variation genetics[mh] 




"interleukin 6 receptor"[tiab] OR receptor, interleukin-6[MeSH] OR IL6R[tiab] OR IL6-receptor[tiab] OR "IL-6 
receptor"[tiab] OR rs4537545[tiab] OR rs8192284[tiab] OR rs4129267[tiab] or rs2228145[tiab]
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